Long-Term Outcomes of Alemtuzumab-Based Reduced-Intensity Conditioned Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Secondary to Myelodysplastic Syndrome

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 1, 2014, Pages 111-117

  Potter, Victoria T ^a   Krishnamurthy, Pramila ^a   Barber, Linda D ^a   Lim, ZiYi ^a   Kenyon, Michelle ^a   Ireland, Robin M ^a   de Lavallade, Hugues ^a   Dhouri, Abdel ^b   Marsh, Judith C W ^a   Marcus, Robert ^a   Devereux, Stephen ^a   Ho, Aloysius ^a   Pagliuca, Antonio ^a   Mufti, Ghulam J ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acute myelogenous leukemia; Alemtuzumab; Myelodysplastic syndrome; Reduced intensity; Transplantatiom

Indexed keywords

ALEMTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PREDICTION; PROPHYLAXIS; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; SIBLING; TREATMENT OUTCOME; YOUNG ADULT;

ACUTE MYELOGENOUS LEUKEMIA; ALEMTUZUMAB; MYELODYSPLASTIC SYNDROME; REDUCED INTENSITY; TRANSPLANTATIOM;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; RECURRENCE; SIBLINGS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 84890934838     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.10.021     Document Type: Article

References (26)

1. Anderson J.E., Appelbaum F.R., Fisher L.D., et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993, 82:677-681.
2. de Witte T., Hermans J., Vossen J., et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000, 110:620-630.
3. Laport G.G., Sandmaier B.M., Storer B.E., et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 2008, 14:246-255.
4. Lim Z.Y., Ho A.Y., Ingram W., et al. Outcomes of alemtuzumab-based reduced-intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol 2006, 135:201-209.
5. Luger S.M., Ringden O., Zhang M.J., et al. Similar outcomes using myeloablative versus reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012, 47:203-211.
6. Soiffer R.J., Lerademacher J., Ho V., et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011, 117:6963-6970.
7. Ho A.Y., Pagliuca A., Kenyon M., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004, 104:1616-1623.
8. Schanz J., Tuchler H., Sole F., et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. JClin Oncol 2012, 30:820-829.
9. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
10. Kroger N., Bornhauser M., Ehninger G., et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 2003, 82:336-342.
11. Tauro S., Craddock C., Peggs K., et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. JClin Oncol 2005, 23:9387-9393.
12. Valcarcel D., Martino R., Caballero D., et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. JClin Oncol 2008, 26:577-584.
13. Lim Z., Brand R., Martino R., et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. JClin Oncol 2010, 28:405-411.
14. de Witte T., Brand R., van Biezen A., et al. Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br J Haematol 2009, 146:627-636.
15. Perez-Simon J.A., Kottaridis P.D., Martino R., et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2prospective studies in patients with lymphoproliferative disorders. Blood 2002, 100:3121-3127.
16. Mielcarek M., Storer B.E., Flowers M.E., et al. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007, 13:1160-1168.
17. Krishnamurthy P., Potter V., Barber L., et al. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2013, 19:562-568.
18. de Lima M., Anagnostopoulos A., Munsell M., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:865-872.
19. Warlick E.D., Cioc A., Defor T., et al. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 2009, 15:30-38.
20. Bokhari S.W., Watson L., Nagra S., et al. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity conditioning hemopoeitic progenitor cell transplantation. Bone Marrow Transplant 2012, 47:528-534.
21. McClune B.L., Weisdorf D.J., Pedersen T.L., et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. JClin Oncol 2010, 28:1878-1887.
22. Castermans E., Hannon M., Dutrieux J., et al. Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age. Haematologica 2011, 96:298-306.
23. Jimenez M., Ercilla G., Martinez C. Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens. Leukemia 2007, 21:1628-1637.
24. Storek J., Witherspoon R.P., Storb R. Tcell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant 1995, 16:413-425.
25. Chakraverty R., Orti G., Roughton M., et al. Impact of invivo alemtuzumab dose before reduced-intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood 2010, 116:3080-3088.
26. Bertz H., Spyridonidis A., Wasch R., et al. Anovel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation. Biol Blood Marrow Transplant 2009, 15:1563-1570.